For immediate release

PRESS RELEASE

BOOST Pharma provides leadership and clinical update

- Seasoned biotech executive Evert Kueppers appointed CEO to accelerate its corporate development incl. fundraising efforts
- Co-founder Dr Lilian Walther Jallow appointed Chief Development Officer to lead all development activities
- Ongoing BOOSTB4 clinical study: all post-natal patients included and 90% first-time dosed; DSMB safety review positive
- Orphan Drug Designation for Osteogenesis Imperfecta (OI) granted in Europe

Copenhagen, February 9, 2022. BOOST Pharma, a clinical-stage biopharmaceutical company focused on the development of novel cell therapy treatments, announces today that Evert Kueppers has been appointed Chief Executive Officer, effective immediately. Current founder CEO, Lilian Walther Jallow, is newly appointed Chief Development Officer. With two ongoing clinical trials, both appointments reflect the growth and further development of BOOST Pharma.

BOOSTB4, an exploratory, open label, multiple dose, multicenter phase I/II trial has to date recruited all 15 patients for the postnatal group from 7 different countries, while almost half of the doses have already been successfully administered. The Data and Safety Monitoring Board (DSMB) has been positive.

"Evert's appointment is very timely, as we see good progress in our clinical trials, despite challenging COVID-19 circumstances, and Evert brings a wealth of business experience that will complement perfectly the scientific and clinical expertise of the BOOST founding team", says Ingelise Saunders, Chairman of BOOST Pharma.

"BOOST Pharma originates from collaborative research at Stockholm-based Karolinska Institute, a world leader in cell therapy research, and we benefit from years of experience from its co-founders, Cecilia Götherström and Magnus Westgren" says Evert Kueppers, as newly appointed CEO. *"I am honored to contribute to the development of a first, potentially effective therapy for patients suffering from Osteogenesis Imperfecta (OI), a serious, inherited rare genetic bone disease, and also to explore the use of our technology to other fields of cell therapy."*

NOTES FOR EDITORS

About BOOST Pharma

Supported by the BioInnovation Institute (BII) in Copenhagen, Denmark, BOOST Pharma is a clinical stage biopharmaceutical company focused on the development of novel cell therapy treatments. The company is currently developing a first-in-class therapy to treat Osteogenesis Imperfecta, a serious, inherited rare genetic disease.

About Osteogenesis Imperfecta

Osteogenesis Imperfecta (OI), also know as Brittle Bone Disease, is a rare and devastating genetic disease, with currently no approved therapies. OI is characterized by fragile bones and reduced bone mass resulting in bones that break easily, loose joints, and weakened teeth. In severe cases, those with OI may experience hundreds of fractures in a lifetime. In addition, people with OI often suffer muscle weakness, early hearing loss, fatigue, curved bones, scoliosis, respiratory problems, and short stature, leading to significant effects on overall health and quality of life. Current treatment of OI is only supportive, focusing on minimizing fractures and maximizing mobility, but to date, there are no FDA or EU approved treatments. OI is estimated to affect between 1 in 15,000 people globally.

About BOOSTB4 trial

“Boost Brittle Bones Before Birth” (BOOSTB4) is an exploratory, open label, multiple dose, multicenter phase I/II trial evaluating safety and efficacy of postnatal, or prenatal and postnatal administration, of allogeneic expanded mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta (OI) compared with a combination of historical and untreated prospective controls. The aim is to develop a first-in-class cell therapy to decrease the severity of inherited OI in un-born and young children. The study received funding from the European Union’s Horizon 2020 Research and Innovation Program (681045) and from the Swedish Research Council (E0720901) with Karolinska Institute as study sponsor.

About Evert Küppers

Evert Küppers is an all-rounded executive with over 25 years of operational experience in pharma & biotech focusing on Business & Corporate Development, Fundraising, and R&D Operations. As biotech CEO in Germany, Switzerland and Belgium/UK, he successfully led cross-functional, international Management and R&D teams and closed multiple investment rounds with international, blue-chip US/EU investors, as well as, private/public investors. Recently, he was a Venture Partner with NLC, a healthtech venture builder, for which he established three MedTech companies (Bologna, Bremen/Vienna, Nijmegen). He is also Managing Director of AMResolute GmbH, a Vienna-based biotech. Evert is an educated biomedical scientist (MSc., Leiden University, NL)

and obtained an MBA degree from the RSM/Erasmus University, NL. He is fluent in Dutch, German, English and Spanish.

For further information, please contact:

Evert Küppers, CEO
Email: evert.kueppers@boostpharma.com